Open an account

Sonoma Pharmaceuticals

SNOA · NASDAQ

$1.15+$0.03 (+2.68%)TodayMarket closed ·
Prev close $1.12

About SNOA

Sonoma Pharmaceuticals, Inc. is a global healthcare leader in the development and production of stabilized hypochlorous acid (HOCl) products. The company is headquartered in Boulder, Colorado and currently employs 168 full-time employees. The company went IPO on 2007-01-26. The firm is engaged in developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its products are all classified as medical devices and categorized as prescription, over-the-counter (OTC) and office dispense products. The company offers both prescription and OTC dermatology products, including Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. In the United States, it offers Microcyn wound and skin care both as an OTC and prescription product. Its eyecare products include Acuiycn Eyelid and Eyelash Hygiene, and Ocucyn Eyelid and Eyelash Cleanser. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections.

Employees
168
Headquarters
Boulder, Colorado
Listed
Jan 26, 2007
Sector
Health Care
Industry
Pharmaceuticals
Website
sonomapharma.com

SNOA key statistics

Market cap
5.51M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
42.22K
Volume
10.59K
Open price
$1.13
High today
$1.17
Low today
$1.13
52 Week high
$4.10
52 Week low
$0.8501

Sonoma Pharmaceuticals (SNOA) at a glance

Sonoma Pharmaceuticals (SNOA) last traded at $1.15, with a market cap of 5.51M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.13 and $1.17. The current price is 1.8% above the day's low and 1.7% below its high.

Volume so far is 10.59K shares, below the average of 42.22K shares a day.

Over the past year Sonoma Pharmaceuticals has ranged from $0.8501 to $4.10, and now sits 9% of the way up that range.

Sonoma Pharmaceuticals met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.32 per share against an estimate of -$0.3162.

SNOA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 34.9% on average.

  1. Q2 FY20: reported -$18.20 per share against an estimate of -$24.07
  2. Q2 FY24: reported -$5.80 per share against an estimate of -$4.90
  3. Q3 FY24: reported -$1.60 per share against an estimate of -$4.28
  4. Q1 FY25: reported -$1.40 per share against an estimate of -$1.22
  5. Q2 FY25: reported -$0.59 per share against an estimate of -$1.02
  6. Q3 FY25: reported -$0.63 per share against an estimate of -$0.7038
  7. Q1 FY26: reported -$0.76 per share against an estimate of -$0.5233
  8. Q2 FY26: reported -$0.32 per share against an estimate of -$0.3162

SNOA news

  • Vandana Singh

    Sonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly Revenue

  • Vandana Singh

    What's Going On With Sonoma Pharma Stock Monday?

  • Avi Kapoor

    Dow Falls Over 150 Points; Procter & Gamble Posts Upbeat Earnings

  • Avi Kapoor

    Nasdaq Gains Over 100 Points; Intel Shares Jump After Strong Q1 Results

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Avi Kapoor

    Dow Falls Over 100 Points; Deere Shares Dip After Q3 Results

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

Similar companies

Companies in the same industry as Sonoma Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.